Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 221Breast 121Tumor-Agnostic 12CNS 10Head & Neck 8Other solid neoplasm 6Endocrine 6Gynecologic 3Genitourinary 3Dermatologic 3Thoracic 2Sarcoma 2NET 2Other 1

Conditions

Neuroendocrine Tumors 2Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Pheochromocytoma 1Pancreatic Neoplasms 1Gastrinoma 1Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

Everolimus 18lanreotide 7Octreotide 7pembrolizumab 6Sunitinib 6Magnetic Resonance Spectroscopy 5lutetium Lu 177 dotatate 4gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3pasireotide 3lenvatinib 3arginyllysine 3Temozolomide 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Capecitabine × NET × Clear all
NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Completed
40 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Columbia University

Phase 2 Completed
41 enrolled 9 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡